anti-CD3/anti-KRAS G12V/HLA-A*03 bispecific T-cell engager (Biocytogen Pharmaceuticals)

N/A

Report date: 2026/03/19 17:12:00

Base Information

Drug Nameanti-CD3/anti-KRAS G12V/HLA-A*03 bispecific T-cell engager (Biocytogen Pharmaceuticals)
Drug Alias NameN/A
ClassificationBiologics > Protein drugs > Recombinant protein > Fusion proteinBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Multispecific monoclonal antibody > Bispecific monoclonal antibodyBiologics > T cell engagers
Mechanisms of ActionAnti-CD3Anti-KRAS G12V
TargetsT cell surface glycoprotein CD3KRAS G12V
Therapy Area/IndicationsNeoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaPreclinical
Originator CompaniesBiocytogen Pharmaceuticals (Beijing) Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesBiocytogen Pharmaceuticals (Beijing) Co Ltd
Inactive CompaniesN/A
Active IndicationsNeoplasms
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A